20951-01-3

Basic information

• Product Name: Pyridin-4-yl-carbamic acid phenyl ester
• Synonyms: Pyridin-4-yl-carbamic acid phenyl ester;Phenyl pyridin-4-ylcarbamate
• CAS NO: 20951-01-3
• Molecular Formula: C₁₂H₁₀N₂O₂
• Molecular Weight: 214.23
• Product Categories: Heterocyclic Building Blocks
• Mol File: 20951-01-3.mol
• Article Data: 20

Chemical Properties

• Melting Point: 148 °C
• Boiling Point: 338.3±24.0 °C(Predicted)
• Appearance: /
• Density: 1.277±0.06 g/cm3(Predicted)
• PKA: 11.80±0.70(Predicted)
• CAS DataBase Reference: Pyridin-4-yl-carbamic acid phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridin-4-yl-carbamic acid phenyl ester(20951-01-3)
• EPA Substance Registry System: Pyridin-4-yl-carbamic acid phenyl ester(20951-01-3)

Safety Data

• Hazardous Substances Data: 20951-01-3(Hazardous Substances Data)

Upstream product

• 504-24-5 4-aminopyridine 
• 102-09-0 bis(phenyl) carbonate 
• 1885-14-9 phenyl chloroformate 

Downstream Products

• 153539-26-5 4-(pyridin-4-yl)semicarbazide 
• 14547-74-1 4-methyl-N-(pyridin-4-yl)benzamide 
• 1620290-70-1 4-(3-((5-(([1,1'-biphenyl]-2-yloxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)ureido)pyridine-1-oxide 
• 1620289-83-9 1-((5-(([1,1'-biphenyl]-2-yloxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)-3-(pyridin-4-yl)urea 
• 1394894-40-6 C₂₃H₂₃ClN₄O₂ 
• 1299487-16-3 1-(4-(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yloxy)phenyl)-3-(pyridin-4-yl)urea 
• 1299487-60-7 1-(4-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)methyl)phenyl)-3-(pyridin-4-yl)urea 
• 1299488-97-3 1-(2-(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)-1H-indazol-5-yl)-3-(pyridin-4-yl)urea 
• 1299488-95-1 1-(1-(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)-1H-benzo[d]imidazol-5-yl)-3-(pyridin-4-yl)urea 
• 1299488-91-7 1-(1-(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)-1H-benzo[d]imidazol-6-yl)-3-(pyridin-4-yl)urea 
• 1299488-82-6 1-(3-fluoro-4-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)(methyl)amino)phenyl)-3-(pyridin-4-yl)urea 
• 1299488-77-9 1-(4-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)(methyl)amino)phenyl)-3-(pyridin-4-yl)urea 
• 1299488-61-1 1-(4-(1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)phenyl)-3-(pyridin-4-yl)urea 
• 1299488-08-6 1-(2-fluoro-4-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)methyl)phenyl)-3-(pyridin-4-yl)urea 

Relevant articles and documents

Compound for specifically enhancing spatial coupling degree of TRPV4-KCa2.3 complex and application of compound

The invention discloses a compound for specifically enhancing the spatial coupling degree of a TRPV4-KCa2.3 complex and an application of the compound, and belongs to the field of chemical medicines.The compound with the structure represented by the general formula (I) is mainly used for uncoupling TRPV4 and KCa2.3 in hypertensive patients, so that two uncoupled proteins can be recoupled, and thenormal state of the two uncoupled proteins can be recovered. Under the normal condition, according to TRPV4 and KCa2.3, TRPV4 receive signals of calcium ions, due to calcium ion inflow, potassium ionoutflow of a downstream KCa2.3 channel is stimulated, vasodilation is achieved through depolarization, and thus the blood pressure of the hypertensive patients is recovered to the normal level.

Design and development of 1,3,4-oxadiazole derivatives as potential inhibitors of acetylcholinesterase to ameliorate scopolamine-induced cognitive dysfunctions

The novel hybrids bearing 4-aminopyridine (4-AP) tethered with substituted 1,3,4-oxadiazole nucleus were designed, synthesized, and evaluated for their potential AChE inhibitory property along with significant antioxidant potential. The inhibitory potenti

4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS

The present invention provides 4,5-dihydroisoxazole derivatives of formula (I), which may be therapeutically useful, more particularly as NAMPT inhibitors. wherein, ring A, L1, L2, X1, X2, X3, Z, R1, R2, R3, R4, R5, m, n, p and q have the meanings given in the specification and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorder, caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPT) in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted 4,5-dihydroisoxazole derivatives of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.